Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children
Status:
Completed
Trial end date:
2018-02-16
Target enrollment:
Participant gender:
Summary
Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in
adults and children older than 3 years of age. This study is being conducted to look at the
safety of EFV, blood levels of EFV, genetic factors that may affect blood levels of EFV, and
how easy it is for infants and young children to take and tolerate EFV. This information will
help recommend the best doses of EFV for children younger than 3 years of age.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)